Skip to Content

Breakthrough: New European Guidelines Suggest Better Management of Fistulas for Patients with Hidradenitis Suppurativa

The new European guidelines for treating hidradenitis suppurativa (HS) were presented at EADV 2024. The guidelines highlight the effectiveness of two new agents, bimekizumab and secukinumab, in treating moderate to severe HS, particularly in addressing draining fistulas. Dr Thrasyvoulos Tzellos explains the guidelines in this MEDtalk.

Thrasyvoulos Tzellos

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top